quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:23·381d
SECFiling
Oncocyte Corporation logo

SEC Form EFFECT filed by Oncocyte Corporation

OCX· Oncocyte Corporation
Health Care
Original source

Companies

  • OCX
    Oncocyte Corporation
    Health Care

Recent analyst ratings

  • Mar 28UpdateLake Street$5.00
  • May 24UpdateStephens-
  • Mar 14UpdateKeyBanc Capital Markets-
  • Mar 11UpdateLake Street$6.00
  • Mar 11UpdateNeedham$4.00
  • Jan 7UpdateStephens & Co.$3.10

Related

  • INSIDER294d
    Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)
  • INSIDER294d
    Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)
  • INSIDER294d
    Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)
  • SEC295d
    Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • SEC310d
    Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR310d
    Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
  • PR339d
    Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
  • SEC344d
    SEC Form DEFA14A filed by Oncocyte Corporation
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022